Mitchel Tate

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7861720/publications.pdf

Version: 2024-02-01

567281 610901 23 935 15 24 citations h-index g-index papers 26 26 26 1631 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications. Frontiers in Physiology, 2018, 9, 114.	2.8	150
2	Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clinical and Translational Immunology, 2018, 7, e1016.	3.8	119
3	Are targeted therapies for diabetic cardiomyopathy on the horizon?. Clinical Science, 2017, 131, 897-915.	4.3	83
4	The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator dh404 protects against diabetes-induced endothelial dysfunction. Cardiovascular Diabetology, 2017, 16, 33.	6.8	80
5	Gremlin1 plays a key role in kidney development and renal fibrosis. American Journal of Physiology - Renal Physiology, 2017, 312, F1141-F1157.	2.7	58
6	Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Research in Cardiology, 2015, 110, 20.	5.9	57
7	Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Research in Cardiology, 2016, 111, 1.	5.9	57
8	Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. Cardiovascular Research, 2022, 118, 212-225.	3.8	47
9	Endogenous Annexin-A1 Regulates Haematopoietic Stem Cell Mobilisation and Inflammatory Response Post Myocardial Infarction in Mice In Vivo. Scientific Reports, 2017, 7, 16615.	3.3	38
10	Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. Diabetes and Vascular Disease Research, 2017, 14, 423-433.	2.0	35
11	Gene therapy targeting cardiac phosphoinositide 3-kinase (p $110\hat{l}_{\pm}$) attenuates cardiac remodeling in type 2 diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H840-H852.	3.2	32
12	Cardioprotective Actions of the Annexin-A1 N-Terminal Peptide, Ac2-26, Against Myocardial Infarction. Frontiers in Pharmacology, 2019, 10, 269.	3 . 5	30
13	Characterising an Alternative Murine Model of Diabetic Cardiomyopathy. Frontiers in Physiology, 2019, 10, 1395.	2.8	29
14	Metabolically-inactive glucagon-like peptide- $1(9\hat{a}\in 36)$ amide confers selective protective actions against post-myocardial infarction remodelling. Cardiovascular Diabetology, 2016, 15, 65.	6.8	25
15	Selective targeting of glucagonâ€like peptideâ€l signalling as a novel therapeutic approach for cardiovascular disease in diabetes. British Journal of Pharmacology, 2015, 172, 721-736.	5 . 4	21
16	The Role of Bone Morphogenetic Proteins in Diabetic Complications. ACS Pharmacology and Translational Science, 2020, 3, 11-20.	4.9	17
17	The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart. Cardiovascular Drugs and Therapy, 2019, 33, 669-674.	2.6	15
18	Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart. Cardiovascular Drugs and Therapy, 2020, 34, 823-834.	2.6	9

MITCHEL TATE

#	Article	IF	CITATION
19	Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives. Clinical Science, 2021, 135, 1369-1387.	4.3	8
20	Bone Morphogenetic Protein 7 Gene Delivery Improves Cardiac Structure and Function in a Murine Model of Diabetic Cardiomyopathy. Frontiers in Pharmacology, 2021, 12, 719290.	3.5	8
21	Current landscape of preclinical models of diabetic cardiomyopathy. Trends in Pharmacological Sciences, 2022, 43, 940-956.	8.7	8
22	Characterisation of the Myocardial Mitochondria Structural and Functional Phenotype in a Murine Model of Diabetic Cardiomyopathy. Frontiers in Physiology, 2021, 12, 672252.	2.8	6
23	Editorial: Translational Approaches for Targeting Cardiovascular Complications of Diabetes. Frontiers in Pharmacology, 2021, 12, 799020.	3.5	O